Business Wire

CA-LIGHTBITS-LABS

Share
Lightbits Grows Revenues By Over 5X in 2020 While Driving Innovation Through Technology Advancements and Patents

Lightbits Labs , the pioneer and leader in NVMe™ over TCP (NVMe/TCP) software-defined storage, increased sales by more than 500 percent through a significant uptick in infrastructure as a service (IaaS), software as a service (SaaS), financial services, and video gaming customers.

Sales growth was fueled in part by the company’s strong partnerships, to which Intel was added in late September and also included new funding from Intel Capital . The partnership is designed to propel development of disaggregated storage solutions to solve the challenges of today’s data center operators who are craving improved storage efficiency and capacity utilization while maintaining compatibility with existing infrastructure without compromising performance and simplicity. This strategic partnership includes technical co-engineering, go-to-market collaboration, as well as the financial investment.

“In so many ways and for so many people 2020 was a very difficult year. Lightbits is fortunate that we were able to keep our employees safe through remote work, while also achieving and exceeding our goals for the year – including growing our customer base, enhancing our products, and expanding our partnerships and investors,” said Eran Kerzner, CEO. “We fully anticipate a strong surge in our sales throughout 2021.”

Last year, Lightbits announced significant product advancements, introducing LightOS™ 2.0 in June enabling full cloud-native persistent storage with high availability. The technological innovation solidified the company's position as a leader in scalable and efficient cloud-native storage that’s easy to consume for customers' private, hybrid, and edge cloud deployments. In December, the company released LightOS™ 2.1 that further enhances high-performance, scalability, and low latency so Lightbits’ customers can unleash hyperscale storage, but at a fraction of the cost of even the most advanced cloud storage offerings. As an example, Lightbits’ LightOS outperforms even the latest Amazon EBS io2 Block Express volumes with 5 times lower latency (200µs), 6 times the IOPS per volume (1.5M), twice the throughput per volume (8GB/s), 4 times larger volume size (256TB), and has features such as resizable volumes and multi-attach that are still roadmap items for io2 Block Express.

Through these advancements, Lightbits expanded the use cases for its patented solutions, including NVMe as a Service, as part of the IaaS umbrella. For financial services, use cases expanded to include database acceleration and Monte Carlo simulation. And under the SaaS umbrella, Lightbits LightOS gained traction as a high-performance replacement for Ceph.

In addition, Lightbits applied for five new patents that were accepted by the U.S. Patent Office, bringing the number of patents held by Lightbits to 20. The newly minted patents improve key functions within the NVMe/TCP storage architecture and help Lightbits protect its innovative approach to improving storage capacity utilization, reducing latency, and improving garbage collection features.

“With its blend of performance and high availability based around industry standards, NVMe/TCP offers a compelling value proposition for those needing extremely high performance in the composable block storage market,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies Group at IDC Research. “Lightbits Labs has significantly contributed to the NVMe/TCP standard and is continuing to improve upon the standard with its latest IP.”

Details on the new and existing Lightbits Labs patents can be found in the links below:

Among the milestones, 2020 drove several notable industry recognitions including:

Additional Resources:

About Lightbits Labs™

Lightbits Labs’ mission is to lead the cloud-native data center transformation by delivering scalable and efficient software defined storage that is easy to consume. Founded in 2016, Lightbits brings the agility of hyperscale storage to private clouds and edge clouds. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that is similar to local flash. Lightbits Labs is backed by strategic investors including Cisco Investments, Dell Technologies Capital, Intel Capital, and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.

Visit www.lightbitslabs.com or contact us at info@lightbitslabs.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye